Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01640912 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
A Phase 1 study, sponsored by RXi Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01640912 is a Phase 1 study that has completed, run by RXi Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT01640912, a Phase 1 study, has completed, sponsored by RXi Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of a single intradermal administration of RXI-109 at small surgical incisions in the abdominal skin that will later be removed during an elective abdominoplasty. The effect of RXI-109 versus placebo on scarring at these incision sites will be evaluated visually and histologically.
Interventions
- DRUG Placebo
- DRUG RXI-109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01640912
The ClinicalTrials.gov registry entry for NCT01640912 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RXi Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01640912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01640912 about?
NCT01640912 is a clinical study titled "Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109". The primary purpose of this study is to evaluate the safety and tolerability of a single intradermal administration of RXI-109 at small surgical incisions in the abdominal skin that will later be removed during an elective abdominoplasty. The effect of RXI-109 versus placebo on scarring at these inc...
What is the current status of trial NCT01640912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-06. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01640912?
The interventions under investigation include: Placebo (DRUG), RXI-109 (DRUG).
Who is sponsoring clinical trial NCT01640912?
This trial is sponsored by RXi Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.